CA2953459A1 - Markers and therapeutic indicators for glioblastoma multiforme (gbm) - Google Patents

Markers and therapeutic indicators for glioblastoma multiforme (gbm) Download PDF

Info

Publication number
CA2953459A1
CA2953459A1 CA2953459A CA2953459A CA2953459A1 CA 2953459 A1 CA2953459 A1 CA 2953459A1 CA 2953459 A CA2953459 A CA 2953459A CA 2953459 A CA2953459 A CA 2953459A CA 2953459 A1 CA2953459 A1 CA 2953459A1
Authority
CA
Canada
Prior art keywords
gbm
proteins
level
tissue
hmox1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2953459A
Other languages
English (en)
French (fr)
Inventor
Dhimankrishna GHOSH
Charles S. Cobbs
Nathan D. Price
Leroy Hood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Systems Biology
Original Assignee
Institute for Systems Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Systems Biology filed Critical Institute for Systems Biology
Publication of CA2953459A1 publication Critical patent/CA2953459A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CA2953459A 2014-06-26 2015-06-26 Markers and therapeutic indicators for glioblastoma multiforme (gbm) Abandoned CA2953459A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017748P 2014-06-26 2014-06-26
US62/017,748 2014-06-26
PCT/US2015/038043 WO2015200823A1 (en) 2014-06-26 2015-06-26 Markers and therapeutic indicators for glioblastoma multiforme (gbm)

Publications (1)

Publication Number Publication Date
CA2953459A1 true CA2953459A1 (en) 2015-12-30

Family

ID=54938849

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2953459A Abandoned CA2953459A1 (en) 2014-06-26 2015-06-26 Markers and therapeutic indicators for glioblastoma multiforme (gbm)

Country Status (6)

Country Link
US (1) US20170176439A1 (enExample)
EP (1) EP3161489A4 (enExample)
JP (1) JP2017522555A (enExample)
AU (1) AU2015279660A1 (enExample)
CA (1) CA2953459A1 (enExample)
WO (1) WO2015200823A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018177982A1 (en) 2017-03-30 2018-10-04 Administración General De La Comunidad Autónoma De Euskadi Sox1 as a prognostic and predictive biomarker in the treatment of central nervous system tumours
CN107653319B (zh) * 2017-10-27 2020-06-30 中南大学湘雅医院 胶质瘤诊断标志物circ8:61680968|61684188及应用
JP7029745B2 (ja) * 2017-12-05 2022-03-04 国立大学法人金沢大学 膠芽腫マーカー及びその使用
JP7211604B2 (ja) * 2017-12-05 2023-01-24 国立大学法人金沢大学 膠芽腫マーカー及びその使用
CN108956997A (zh) * 2017-12-29 2018-12-07 广西壮族自治区人民医院 Cd151蛋白表达量elisa检测方法及试剂盒
CN110211634B (zh) * 2018-02-05 2022-04-05 深圳华大基因科技服务有限公司 一种多组学数据联合分析的方法
CA3116552A1 (en) * 2018-10-14 2020-04-23 Lantern Pharma Inc. Methods for the treatment of solid tumor cancers using illudins and biomarkers
CN114267447B (zh) * 2021-09-26 2025-05-06 吴安华 一种预测胶质母细胞瘤免疫微环境、预后及治疗敏感性的基因集及系统和方法
PL446389A1 (pl) * 2023-10-15 2025-04-22 Warszawski Uniwersytet Medyczny Nowe markery do diagnozowania glejaka wielopostaciowego oraz ich zastosowania

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517046A (ja) * 2003-12-24 2007-06-28 サイオス・インコーポレーテツド Ｔｇｆ−ベータ阻害剤による悪性神経膠腫の治療
CA2612021A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
CA2679943A1 (en) * 2007-03-02 2008-09-12 Board Of Regents, The University Of Texas System Multigene assay to predict outcome in an individual with glioblastoma
WO2009014565A2 (en) * 2007-04-26 2009-01-29 Ludwig Institute For Cancer Research, Ltd. Methods for diagnosing and treating astrocytomas
JP2013502421A (ja) * 2009-08-21 2013-01-24 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー 癌治療のためのｃｄ４４融合タンパク質の使用方法
US8404437B2 (en) * 2011-03-29 2013-03-26 Taipei Veterans General Hospital MicroRNA as a cancer progression predictor and its use for treating cancer

Also Published As

Publication number Publication date
AU2015279660A1 (en) 2017-01-19
EP3161489A4 (en) 2018-04-18
WO2015200823A1 (en) 2015-12-30
EP3161489A1 (en) 2017-05-03
US20170176439A1 (en) 2017-06-22
JP2017522555A (ja) 2017-08-10

Similar Documents

Publication Publication Date Title
CA2953459A1 (en) Markers and therapeutic indicators for glioblastoma multiforme (gbm)
US9746481B2 (en) Biomarkers of brain injury
CN113025713A (zh) 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用
Zhou et al. Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue
Häggmark et al. Plasma profiling reveals three proteins associated to amyotrophic lateral sclerosis
Ghosh et al. A cell-surface membrane protein signature for glioblastoma
Eagle et al. Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia
US9140687B2 (en) Renal cell carcinoma biomarkers
KR20090034961A (ko) 폐암 진단 검사
US20230047712A1 (en) Methods of Treatments Based Upon Molecular Response to Treatment
Liang et al. Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes
AU2011241174A1 (en) Method and kit for cancer diagnosis
EP2605017A1 (de) Markersequenzen für gynäkologisches Malignom und deren Verwendung
KR101390590B1 (ko) 췌장암 재발 예후 예측용 마커 및 이의 용도
US20150338412A1 (en) Composition for diagnosis of lung cancer and diagnosis kit for lung cancer
KR20140002149A (ko) 췌장암 진단용 마커 및 이의 용도
Kim et al. Multiple reaction monitoring of multiple low-abundance transcription factors in whole lung cancer cell lysates
CN116490776A (zh) 用于检测和治疗卵巢癌的方法
WO2019149736A1 (en) Method to predict the need for therapy of patients suffering from chronic lymphocytic leukemia
EP4558824A2 (en) Methods for the detection and treatment of ovarian cancer
EP3652541A1 (en) Combination of markers for diagnosing cancer
Picolo et al. Salivary proteomics profiling reveals potential biomarkers for chronic kidney disease: a pilot study
US20210080465A1 (en) SH2 domain-based prognostic biomarker for chronic lymphocytic leukemia
US20250271439A1 (en) Proteomic signature of plasma extracellular vesicles classifies response to doxorubicin and cancer
CN106093241A (zh) 可用于检测喉癌的标志物及其用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831